Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Unity Biotechnology, Inc. - Common Stock (NQ:UBX)

0.9602 -0.1098 (-10.26%)
Streaming Delayed Price Updated: 1:39 PM EDT, May 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Unity Biotechnology, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Expert Ratings for Unity Biotechnology
Via Benzinga
Nasdaq Edges Lower; Unity Biotechnology Shares Plummet
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite trading lower on Monday. The Dow traded up 0.91% to 32,530.40 while the NASDAQ fell 0.09% to 11,813.90. The S&P 500, also... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Jounce Therapeutics Shares Are Trading Higher By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares jumped 59.6% to $0.2513. Crown Electrokinetics said it has entered into an agreement with a leading infrastructure solutions provider. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  Thursday saw 177 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday, 89 stocks made new 52-week lows. 
Via Benzinga
Why Is Codiak BioSciences (CDAK) Stock Down 52% Today?
Codiak BioSciences (CDAK) stock is falling hard on Monday after the company announced plans for an asset sale via a Chapter 11 bankruptcy. 
Via InvestorPlace
Gold Drops Over 1%; First Citizens BancShares Shares Spike Higher
U.S. stocks traded higher midway through trading, with the Dow Jones gaining over 100 points on Monday. The Dow traded up 0.42% to 32,372.55 while the NASDAQ rose 0.01% to 11,825.46. The S&P 500, also... 
Via Benzinga
Why Is Unity Biotechnology (UBX) Stock Down 52% Today?
Unity Biotechnology (UBX) stock is taking a beating on Monday after revealing results from its Phase 2 clinical trial of UBX1325. 
Via InvestorPlace
UNITY Biotechnology's Wet AMD Candidate Flunks On Non-Inferiority Threshold Compared To Regeneron's Drug
UNITY Biotechnology Inc (NASDAQ: UBX) announced results from Part A of the Phase 2 ENVISION study of UBX1325 in patients with wet age-related macular degeneration (AMD) who were not achieving optimum... 
Via Benzinga
US Stocks Open Higher; Dow Rises 200 Points
U.S. stocks traded higher this morning, with the Dow Jones gaining around 200 points on Monday. Following the market opening Monday, the Dow traded up 0.64% to 32,443.64 while the NASDAQ rose 0.20% to... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
UNITY Biotechnology Announces Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration
From Unity Biotechnology, Inc.
Via GlobeNewswire
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
From Unity Biotechnology, Inc.
Via GlobeNewswire
UNITY Biotechnology to Participate in the Cowen 43rd Annual Health Care Conference
From Unity Biotechnology, Inc.
Via GlobeNewswire
UNITY Biotechnology to Participate in the SVB Securities Global Biopharma Conference
From Unity Biotechnology, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
UNITY Biotechnology to Host Investor Call to Review Data from the UBX1325 Program and Provide an Overview of the ENVISION Wet AMD Study
From Unity Biotechnology, Inc.
Via GlobeNewswire
UNITY Biotechnology Reports Granting of New Employment Inducement Award
From Unity Biotechnology, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 283 companies set new 52-week lows. 
Via Benzinga
UNITY Biotechnology, Inc. Reports Third Quarter 2022 Financial Results and Business Updates
From Unity Biotechnology, Inc.
Via GlobeNewswire
Unity Biotechnology (UBX) Stock Pops on Positive Study Data
Unity Biotechnology (UBX) stock is gaining on Tuesday after the company released results from a Phase 2 clinical trial of UBX1325. 
Via InvestorPlace
UNITY Biotechnology Announces Positive 24-Week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
From Unity Biotechnology, Inc.
Via GlobeNewswire
UNITY Biotechnology to Host Program Update on BEHOLD, the Phase 2 Clinical Trial of UBX1325 in Patients with Diabetic Macular Edema
Program Update with retinal expert Arshad M. Khanani, M.D., M.A., FASRS, to be held on Tuesday, November 1 at 5:00 a.m. PT/8:00 a.m. ET 
From Unity Biotechnology, Inc.
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time for another dive into the biggest pre-market stock movers as we get a start on Thursday trading with the latest news! 
Via InvestorPlace
UNITY Biotechnology Announces Reverse Stock Split Effective at 5:00 PM Eastern Time Today
UBX common stock expected to begin trading on a split-adjusted basis on October 20, 2022 
From Unity Biotechnology, Inc.
Via GlobeNewswire
UNITY Biotechnology’s Investor and Analyst Day to Highlight UBX1325 Program in Age-Related Diseases of the Eye
From Unity Biotechnology, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback